Investigation of satisfaction, efficacy and safety after switching from daily GLP-1 receptor agonist to weekly dulaglutide in patients with type 2 diabetes -open label, randomized, parallel group controlled clinical study-
Phase of Trial: Phase IV
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Dulaglutide (Primary) ; HM 12525A
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 23 Aug 2017 Status changed from active, no longer recruiting to completed.
- 20 Jul 2017 Planned End Date changed from 30 Nov 2018 to 11 Jul 2017.
- 24 Apr 2017 Status changed from not yet recruiting to active, no longer recruiting.